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treatment. Nonetheless, among the subgroup of patients who
underwent monitoring during both the initial treatment and study
drug discontinuation periods (n 5 163), ischemia was less fre-
quently observed during both monitoring periods in the enoxaparin
group (18.4% vs. 32.2%, p 5 0.045 and 25% vs. 46%, p 5 0.005,
respectively). Further, the time to first ischemic episode was
significantly earlier among UFH-treated patients, consistent with
a superior early antithrombotic effect of enoxaparin and a reduction
in the composite clinical end point of death, myocardial infarction
(MI), and need for urgent revascularization (3).
Therefore, we believe that enoxaparin has been shown to be
superior to UFH based upon the consistent and statistically
significant reductions in the composite and double (death/MI) end
points in ESSENCE and TIMI 11B (4). In contrast, “extending
the duration and slower weaning” of UFH is an unproven method
of administration, and, in fact, the cost-savings realized with
enoxaparin ultimately make it the less expensive option (5).
Shaun G. Goodman, MD, FACC
Anatoly Langer, MD, FACC
Division of Cardiology
St. Michael’s Hospital
30 Bond Street
Room 9-005 Queen
Toronto, ON M5B 1W8, Canada
E-mail: goodmans@smh.toronto.on.ca
PII S0735-1097(01)01261-X
REFERENCES
1. Goodman SG, Barr A, Sobtchouk A, et al. Low molecular weight
heparin decreases rebound ischemia in unstable angina or non-Q-wave
myocardial infarction: the Canadian ESSENCE ST Segment Moni-
toring Substudy. J Am Coll Cardiol 2000;36:1507–13.
2. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoag-
ulant treatments on von Willebrand factor release in unstable angina.
J Am Coll Cardiol 2000;36:110–4.
3. Lopez-Sendon J, Antman EM, McCabe CH, et al. Superiority of
enoxaparin over unfractionated heparin in unstable angina occurs early
in treatment: results from TIMI 11B (abstr). J Am Coll Cardiol
1999;33:352A.
4. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment
effect of enoxaparin for unstable angina/non-Q-wave myocardial infarc-
tion: TIMI 11B–ESSENCE meta-analysis. Circulation 1999;100:
1602–8.
5. O’Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman
S. Is the use of low-molecular-weight heparin (enoxaparin) in acute
coronary syndrome patients cost saving in Canada? Am Heart J
2000;139:423–9.
Failure of Right Ventricular
Recovery of Fallot Patients After
Pulmonary Valve Replacement:
Delay of Reoperation or Surgical Technique?
We read with great interest and surprise the article published by
Therrien et al. in the November issue of the Journal (1). These
results are extremely disappointing. All the physicians familiar
with the treatment of patients with repaired tetralogy of Fallot
share the idea that one should not wait too long before implanting
a valve in the right ventricular outflow tract of patients presenting
with dilated right ventricle. Extremely dilated right ventricles
might not benefit from valvulation as much as moderately dilated
ones. However, it is extremely surprising that all patients operated
on in a major center like Toronto showed neither clinical improve-
ment nor regression of ventricular volumes after reoperation.
Although their patients were operated on quite late, we wonder
whether their unexpectedly bad results might not be related to
another reason than the delay for reoperation. The Toronto team
has the peculiarity of implanting bioprosthetic material in the right
ventricular outflow tract of these patients. Almost all patients
received a stented bioprosthesis varying in size between 25 and
33 mm in diameter. It is noteworthy that true diameters of the
outer rings are even larger than these measurements. The only way
to implant these rather bulky bioprostheses at the level of the
pulmonary annulus is to cover them with a patch extending from
the main pulmonary artery to the infundibulum of the right
ventricle. The immediate effect of this patching is to further
increase the size of the right ventricular cavity, which may at least
partly explain the fact that no decrease was observed in end-systolic
and end-diastolic volumes of these patients after reoperation. We
have recently shown that pulmonary insufficiency might not be the
leading factor causing right ventricular dilation after repair of
tetralogy of Fallot, and we suspect that the contractile function of
the pulmonary infundibulum may play a role in the preservation of
right ventricular function (2). Adding a patch to this already
weakened area might further contribute to the deterioration of this
function.
Like others, we believe that homografts are the ideal valve
substitute for the right ventricular outflow tract because they offer
a better effective orifice area, and they do not necessitate a patch
enlargement. Although 40% of the patients presented in this series
had an aneurysm resection, it is not clear whether the researchers
believe that they effectively reduced right ventricular size at the
time of the procedure.
In conclusion, we wonder whether the extremely poor results
presented by Therrien et al. (1) might not be at least partially
explained by their surgical technique rather than by the delay in the
reoperation. The insertion of a patch in the already dilated area of
the pulmonary infundibulum might further impede right ventric-
ular function and as such increase rather than decrease right
ventricular volumes.
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REPLY
We appreciate the opportunity to reply to the letter sent by Dr.
d’Udekem and colleagues concerning the article we recently
published in JACC.
Although we are grateful for their interest in our work, we
would like to address the issues they have raised. First, their
statement that “. . . all patients operated on . . . showed neither
clinical improvement nor regression of ventricular volumes after
reoperation . . . ” is incorrect. As our article clearly stated, most of
our symptomatic patients had a significant clinical improvement
postoperatively (24% NYHA class $ III preoperatively vs. 0%
postoperatively, p , 0.001) (1). Unfortunately, this could not be
confirmed objectively (the same mean duration of exercise and
external workload was achieved both pre- and postoperatively).
Furthermore, although the mean right ventricular volume and
function did not improve postoperatively, about one-third of our
patients did show such improvement as depicted in Figures 1, 2
and 3 of our article (1). Unfortunately, the relatively small number
of patients made it impossible to determine which of the many
factors analyzed favored such a response. Finally, we disagree with
the statement that “the . . . effect of this [bulky bioprosthesis] . . .
is to further increase the size of the right ventricular cavity” . . . and
impede contraction of the pulmonary infundibulum by virtue of its
extensive transannular patching. They are correct that we do
enlarge the outflow tract to accommodate as large a prosthesis as
possible, but the patch to do this is largely from the annulus
distally. Proximal to the annulus, the patch extends into the
infundibulum a distance of 10 to 15 mm. We do not believe that
a 10 to 15 mm incision below the pulmonary annulus would have
an important impact on right ventricular volume and function. We
do agree, however, that any incision in the right ventricle should be
avoided or minimized as much as possible in order to potentiate
maximal postoperative functional recovery.
The issue of pulmonary valve replacement in adults late after
repair of tetralogy of Fallot remains a controversial one and we
again thank Dr. d’Udekem and colleagues for their interest in our
work.
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A Real Smoker’s Paradox
The article by van Domburg et al. (1) in the September issue of the
Journal presented detailed but not unexpected findings with regard
to the hazards of cigarette smoking. However, I wonder whether
the authors are aware that in Figure 2 of their paper, there is a
graph which implies that the survival rate of cigarette smokers who
quit after their bypass operation is significantly better than those
who continue to smoke, but also significantly better than those
who have never smoked. One would have to conclude from this
data that the best chances of survival are among those who smoke
up until the time of their surgery and then quit, rather than never
to smoke at all. This would truly be a smoker’s paradox if in fact
it is correct!
I would appreciate some explanation from the authors.
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REPLY
We appreciate the comments of Dr. Shander regarding our recent
article in JACC (1). In his comments he concluded that “the best
chances of survival are among those who smoke up until the time
of their surgery and then quit rather than never to smoke at all.”
We have proven that patients who quit smoking after bypass
surgery are significantly better off than those who continue to
smoke. However, in our study we only compared the patients who
quit smoking with patients who continued smoking. Because of its
irrelevancy, we did not compare the patients who quit smoking
with patients who did not smoke. Furthermore, we did not use the
term “never smoked” but used the term “nonsmoking.” We did not
distinguish between patients who have never smoked and ex-
smokers (patients who had stopped smoking before the time of
surgery), and we combined these two groups into one nonsmokers’
group at the time of surgery. The smoking habits at the time of
surgery did not influence survival during the follow-up period.
This smoker’s paradox is partly explained by the difference in
baseline characteristics such as an age difference (smokers were
four years younger than nonsmokers). Another explanation could
be selection bias, as many smokers tend to die of fatal myocardial
infarctions before they have the chance to undergo coronary bypass
surgery (2).
Finally, the survival rates of the nonsmokers were probably
positively influenced by the ex-smokers. In conclusion, the worse
condition of the nonsmokers as compared with the smokers at the
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